Fewer incidents of thrombosis were recorded after the second dose of AstraZeneca's Vaxzevria vaccine, according to findings that the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is recommending be added to the product information, according to a statement on Friday.
As reported, the PRAC found on the basis of aggregated data that the majority of potential cases of "thrombosis with thrombocytopenia syndrome" (TTS) were recorded after the first dose and significantly fewer after the second dose.
Specifically, of the 1809 cases recorded worldwide, 1643 were recorded after the first dose and 166 after the second.
(CNA)
CNA - Giorgos Kakouris
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
